MU101_20_001_WL - Wegleitung | 9.1 | 13.06.2023 11 /12
11 Information on submitting an application for a variation “Change
to the product information” in the context of signal evaluation by
Swissmedic
In the context of signal evaluation by Swissmedic, an official decision will be issued on the final
wording for modified medicinal product information and/or packaging, according to the signal process,
and the signal closed with the decision.
Once an official decision has been issued, the variation to Swissmedic should be submitted within 30
calendar days as a C.I.1 a) type IA
IN
application. The legal basis is provided by Art. 21 TPO.
The updated product information texts must be published promptly, but at the latest by 70 days after
the official decision on the signal.
Please note, however, that these applications for a variation cannot be submitted as part of a multiple
application.
The signal process in detail:
If the MAH has already submitted the draft version of the variation of the product information in the
correspondence language with the Signal Notification Form, Swissmedic will review the draft
version and, if the wording is acceptable, issue its official decision directly. If the wording has to be
ameneded, Swissmedic will inform the MAH by a letter.
If Swissmedic prescribes a modification of medicinal product information in the course of its
evaluation of a signal, the MAH will be sent the wording of the modified text by letter (providing the
wording has not already been submitted by the MAH). They will then have an opportunity to
comment on the measures and the wording of the modification.
Unless the MAH informs Swissmedic otherwise within the specified deadline, the Agency will
assume that they consent. Swissmedic will then issue its official decision on the text and complete
the signal with that decision.
If the MAH does inform Swissmedic otherwise, the Agency will review their reply and notify them
of the results of the evaluation and the resulting requirements by means of a preliminary decision.
The MAH then again has the opportunity to make a statement on the requirements in a response
to the preliminary decision. After reviewing the statement, the measures will be ordered based on
the outcome of the evaluation in the form of a decision.
Swissmedic can propose a general wording when extensive and complex changes are required.
In such cases, the MAH should submit the final text in the correspondence language, with
comments. After reviewing the proposed text, Swissmedic will notify the MAH of the outcome of its
review, including any text corrections, in the form of a preliminary decision.
An official decision on the final text will be issued once the MAH has replied to the preliminary
decision.
Once the official decision on the wording has been issued in the context of signal closure, the
modified medicinal product information and/or packaging texts must be submitted as a C.I.1 a) type
IA
IN
application. Whenever you submit an application, please reference the corresponding signal ID.
Application types for applications of variations involving medicinal products with known active
substances without innovation, biosimilars and co-marketing preparations can be found in the
currently valid version of the relevant guidance documents.